Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.
Cumali EfeRenumathy DhanasekaranCraig Steven LammertBerat EbikFatima Higuera-de la TijeraCostica AlomanAli Rıza CalışkanMirta PeraltaAlessio GerussiHatef MassoumiAndreea M CatanaMurat TorgutalpTugrul PurnakCristina RigamontiAndres Jose Gomez AldanaNidah KhakooHüseyin KacmazLeyla NazalShalom Z FragerNurhan DemirKader IrakZeynep Melekoğlu EllikH. Yasemin BalabanKadri AtayFatih ErenLaura CristoferiErsin BatıbayÁlvaro UrzúaRomee SnijdersMurat KıyıcıMurat AkyıldızNazım EkinRotonya M CarrMurat HarputluoğluIbrahim HatemiManuel MendizabalMarcelo SilvaRamazan IdilmanMarina SilveiraJoost P H DrenthDavid N AssisEinar BjörnssonJames L BoyerPietro InvernizziChyntia LevyThomas D SchianoEzequiel RidruejoStaffan WahlinPublished in: Hepatology (Baltimore, Md.) (2021)
This international, multicenter study reveals that patients with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD. Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH. Maintenance of immunosuppression during COVID-19 was not associated with increased risk for severe COVID-19 but did lower the risk for new-onset liver injury during COVID-19.